Diffuse Large B-Cell Lymphoma (DLBCL)

DBCOND0028221Hemic and Lymphatic DiseasesImmunoproliferative Disorders

Diffuse Large B-Cell Lymphoma (DLBCL) is the indication for 3 drugs in DrugBank. It is covered by 8 curated, structured indications.

Also known as
Diffuse Large B Cell Lymphoma · Diffuse large B-cell lymphomas · Diffuse Large B-Cell Lymphoma · Diffuse Large Cell Lymphoma · Diffuse Large-Cell Lymphoma
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM000605363ICD-10C83.3SNOMED CT109969005MedDRA10012819UMLSC0079744

What you can answer from here — as of November 14, 2026

3Indicated drugsWith each drug's targets and mechanism
Listed above
8Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
1,150Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Diffuse Large B-Cell Lymphoma (DLBCL) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In